Finite Versus Indefinite Nucleos(t)ide Analogue Therapy in HBeAg‑Negative Chronic Hepatitis B: Meta‑Analysis of Randomized Trials.

J Viral HepatOct 7, 2026
Clinical ResearchGastroenterology

Demver P Gomez, Wilmyr F Hababag

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the efficacy and safety of finite versus continuous nucleos(t)ide analogue therapy in HBeAg-negative adults with chronic hepatitis B. Analyzing data from four randomized controlled trials involving 357 participants, the study found that discontinuation of therapy increased HBsAg loss (RR 5.02), but also significantly raised the risk of virologic relapse (RR 23.09) and retreatment (RR 21.94).

Key findings

  • Discontinuation of therapy increased HBsAg loss compared to continuation (RR 5.02).
  • Finite therapy significantly increased the risk of virologic relapse (RR 23.09).
  • Retreatment rates were also higher with finite therapy (RR 21.94).
  • No serious adverse events or hepatic decompensation were reported.

Why it matters

Understanding the balance between potential benefits and risks of finite nucleos(t)ide analogue therapy is crucial for clinicians managing chronic hepatitis B, particularly in selecting appropriate treatment strategies for patients aiming for functional cure.

Source

PubMed · PMID 42834661

Published in J Viral Hepat. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.